Kurt Budelmann, MD
Internal Medicine · Greenville, SCNPI 1295760973
Payments from drug & device makers
Across 424 payments — averaging $21.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- GSK$1K
- Sanofi-aventis U.S. LLC$727
- AbbVie$647
- AstraZeneca$549
- Johnson & Johnson$528
- plus $5K from 30 others
What the payments were for
- Food & beverage$9,09899%
- Education$871%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 53 | $1,184 |
| GSK | 41 | $1,037 |
| Sanofi-aventis U.S. LLC | 27 | $727 |
| AbbVie(2 entities) | 57 | $647 |
| AstraZeneca | 20 | $549 |
| Johnson & Johnson | 19 | $528 |
| Amgen | 30 | $490 |
| Lilly USA, LLC | 15 | $475 |
| Boehringer Ingelheim | 12 | $421 |
| Pfizer | 21 | $394 |
| Intuity Medical Inc | 7 | $391 |
| Bayer | 22 | $314 |
| Inari Medical, Inc. | 4 | $268 |
| Astellas Pharma US Inc | 7 | $188 |
| Mannkind Corporation | 9 | $153 |
| Novartis | 9 | $152 |
| Abbott | 8 | $151 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $149 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Amarin Pharma, Inc. | 8 | $124 |
| Dexcom, Inc. | 8 | $114 |
| Philips North America LLC | 5 | $100 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $94 |
| Esperion Therapeutics, Inc. | 5 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $59 |
| Daiichi Sankyo Inc. | 3 | $59 |
| Merck | 4 | $54 |
| Genentech USA, Inc. | 3 | $45 |
| Exact Sciences | 2 | $31 |
| Biosense Webster, Inc. | 1 | $19 |
| Seqirus USA Inc | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Therapeuticsmd, Inc. | 1 | $12 |
| Boston Scientific | 1 | $11 |
| Sanofi Pasteur Inc. | 1 | $11 |
| Sumitomo Pharma America, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$233
- INVOKANA$224
- FLOWTRIEVER CATHETER, S$197
- CT THROMBECTOMY SYSTEM KIT$197
- AREXVY$128
- MOUNJARO$125
- VOQUEZNA$125
- BEXSERO$119
- TRELEGY ELLIPTA$116
- SOLIQUA 100/33$114
- RYBELSUS$114
- ZEPBOUND$112
- JARDIANCE$111
- TOUJEO$110
- VRAYLAR$105
- FARXIGA$105
- PREVNAR 20$104
- Pogo Automatic Blood Glucose Monitoring System$103
How this compares
$9,184 in reported general payments places this provider in the 90th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 196 | $226,608 |
| RybelsusSemaglutide | 155 | $195,098 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 123 | $111,102 |
| EliquisApixaban | 96 | $102,912 |
| OzempicSemaglutide | 65 | $92,311 |
| MounjaroTirzepatide | 78 | $84,124 |
| FarxigaDapagliflozin Propanediol | 65 | $67,118 |
| Tresiba Flextouch U-200Insulin Degludec | 51 | $58,564 |
| JanuviaSitagliptin Phosphate | 47 | $56,154 |
| TrulicityDulaglutide | 39 | $46,112 |
| XareltoRivaroxaban | 45 | $42,588 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $40,100 |
| MyrbetriqMirabegron | 44 | $32,831 |
| BelsomraSuvorexant | 50 | $31,754 |
| GlyxambiEmpagliflozin/Linagliptin | 13 | $22,539 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $1,184 | $287,409220 claims |
| Boehringer IngelheimJardiance, Glyxambi | $421 | $249,148209 claims |
| Lilly USA, LLCMounjaro, Trulicity | $475 | $130,236117 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $727 | $111,102123 claims |
| PfizerEliquis | $394 | $102,91296 claims |
| MerckJanuvia, Belsomra | $54 | $87,90797 claims |
| AstraZenecaFarxiga, Symbicort | $549 | $76,15387 claims |
| Johnson & JohnsonXarelto | $528 | $42,58845 claims |
| GSKTrelegy Ellipta | $1,037 | $40,10047 claims |
| Astellas Pharma US IncMyrbetriq | $188 | $32,83144 claims |
| AbbVieLinzess, Synthroid | $647 | $24,11780 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Greenville
- Bruce GrayGreenville$254K
- Mark PurcellGreenville$165K
- Melanie GreeneGreenville$142K
- Zion LammGreenville$118K
- Lisa DarbyGreenville$43K
- Uchenna DikeGreenville$31K
- Siddesha ArashinagundiGreenville$13K
- Jill SullivanGreenville$12K
- Sudhhirkumar PatelGreenville$12K
- Rica SantiagoMt Pleasant$10.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.